LuciPona 45 — Ponatinib 45 mg Tablets, 30 Tablets

LuciPona 45 mg is supplied as film-coated tablets for oral administration. The film coating protects the active ingredient from environmental factors and ensures product stability.

Qualitative and Quantitative Composition per Tablet:

• • Active Ingredient: Ponatinib Hydrochloride INN equivalent to Ponatinib — 45 mg.
• • Tablet Core Excipients: Lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate.
• • Film Coating Excipients: Hypromellose, titanium dioxide (I.P.), macrogol, talc.

Packaging Configuration: 45 mg tablets are supplied in bottles or blister packs containing 30 tablets. The package contains 30 tablets, corresponding to a 30-day standard continuous course of therapy (1 tablet once daily). The bottle is packaged in an official Lucius Pharmaceuticals carton with prescribing instructions and security features.

Pharmacodynamics:
Ponatinib is a pan-BCR-ABL tyrosine kinase inhibitor. It is engineered to bind with high affinity to the ATP-binding pocket of BCR-ABL, avoiding steric hindrance caused by the T315I mutation. Ponatinib also inhibits VEGFR, PDGFR, FGFR, FLT3, KIT, and SRC family kinases, blocking cell proliferation and pro-angiogenic signaling in malignant cells.

Pharmacokinetics:

• • Absorption: Peak plasma concentrations ($C_{max}$) occur within 6 hours post-dose. Food intake has no clinically relevant effect on ponatinib absorption.
• • Distribution: Highly bound to human plasma proteins (>99%). Apparent volume of distribution exceeds 1000 L.
• • Metabolism: Primary hepatic metabolism via CYP3A4, with minor contributions from CYP2D6, CYP2C8, and esterases/epoxide hydrolase.
• • Elimination: Terminal elimination half-life ($T_{1/2}$) is approximately 24 hours. Excreted mainly in feces (~87%) and minimally in urine (~5%).

LuciPona 45 mg is indicated for adult patients with:

• • Chronic Myeloid Leukemia (CML): Chronic, accelerated, or blast phase CML resistant or intolerant to prior dasatinib or nilotinib therapy; or with confirmed T315I mutation.
• • Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Resistant or intolerant to dasatinib; or with confirmed T315I mutation.

Treatment with LuciPona 45 mg should be initiated and managed by a physician experienced in hematology and oncology.

Method of Administration:
For oral use. Swallow tablets whole with water at approximately the same time every day, with or without food. Do not chew, crush, or break tablets.

Standard Dosing Regimen:

• • Starting Dose: 45 mg (1 tablet) once daily continuously.
• • Dose Reduction upon Response: In chronic phase CML patients who achieve a major cytogenetic response (MCyR), dose reduction to 30 mg or 15 mg daily should be considered to minimize the risk of arterial occlusive events.
• • Treatment Duration: Continue until disease progression or unmanageable toxicity.

Missed Dose: If a dose is missed, do not take an extra dose. Take the next dose at the regular scheduled time the following day.

Administration of LuciPona 45 mg is contraindicated in:

• • Hypersensitivity: Hypersensitivity to ponatinib or any excipient in the tablet.
• • History of Myocardial Infarction / Stroke: Recent severe arterial thrombosis or unstable cardiovascular status.
• • Pregnancy and Lactation: Contraindicated during pregnancy and breastfeeding.
• • Pediatric Population: Patients under 18 years of age.

Ponatinib is metabolized via CYP3A4, leading to potential drug interactions.

Key Drug Interactions:

• • Strong CYP3A4 Inhibitors: Co-administration with ketoconazole, itraconazole, clarithromycin, or grapefruit juice increases ponatinib plasma exposure. If co-administration is necessary, reduce starting dose of LuciPona to 30 mg.
• • Strong CYP3A4 Inducers: Co-administration with rifampin, carbamazepine, or St. John's Wort reduces ponatinib exposure and therapeutic efficacy.
• • Gastric pH Elevating Agents: Proton pump inhibitors and H2-receptor antagonists may slightly reduce ponatinib solubility.

Pregnancy:
Ponatinib can cause fetal harm and congenital malformations. LuciPona is contraindicated during pregnancy. Females of reproductive potential must use effective contraception during treatment and for 3 weeks after the last dose.

Lactation:
It is unknown whether ponatinib is excreted in human milk. Breastfeeding must be discontinued during treatment with LuciPona.

LuciPona 45 mg carries risk of significant adverse reactions requiring clinical monitoring.

Serious Warnings & Adverse Reactions:

• • Arterial Occlusions: Risk of myocardial infarction, stroke, arterial stenosis, and peripheral vascular occlusion. Cardiovascular monitoring is recommended.
• • Venous Thromboembolism: Deep vein thrombosis and pulmonary embolism.
• • Hypertension: Common, requiring antihypertensive management.
• • Hepatotoxicity: Elevated ALT, AST, bilirubin; potential acute hepatic failure.
• • Pancreatitis: Elevated serum lipase/amylase, acute pancreatitis.
• • Gastrointestinal & General: Abdominal pain, constipation, diarrhea, rash, dry skin, fatigue, headache, myalgia, thrombocytopenia, neutropenia.

Symptoms:
Overdose may cause severe hypertension, acute pancreatitis, profound myelosuppression, and vascular occlusive events.

Treatment:
No specific antidote exists. In case of overdose, discontinue medication, administer supportive care, and monitor vital signs and organ functions.

Storage Requirements for LuciPona 45 mg:

• 🌡️ Temperature: Store below 30°C. Do not freeze.
• ☀️ Protection: Keep in original container to protect from light and moisture.
• 👶 Safety: Keep out of reach of children.
• ⏳ Shelf Life: 24 months from manufacturing date. Rx Only.

Lucius Pharmaceuticals implements security features for LuciPona 45 mg packaging:

• ✅ Security Hologram: Official "LUCIUS" hologram sticker with scratch-off QR verification code on top box flap.
• ✅ Corporate Logo: "LUCIUS PHARMACEUTICALS" wordmark with blue crystal graphic.
• ✅ Design Features: "LuciPona" title with red accent, bright red box highlighting "45mg" dosage, and brand graphic element at the bottom right.
• ✅ Batch Identification: Printed Lot No., Mfg Date, and Exp Date on the box side panel.